Annexon, Inc. (ANNX)
4.50
-0.17
(-3.64%)
USD |
NASDAQ |
Sep 09, 10:31
Annexon Debt to Equity Ratio : 0.1325 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1325 |
| March 31, 2026 | 0.1244 |
| December 31, 2025 | 0.1238 |
| September 30, 2025 | 0.1669 |
| June 30, 2025 | 0.1388 |
| March 31, 2025 | 0.1161 |
| December 31, 2024 | 0.0988 |
| September 30, 2024 | 0.0893 |
| June 30, 2024 | 0.0836 |
| March 31, 2024 | 0.1173 |
| December 31, 2023 | 0.1251 |
| September 30, 2023 | 0.2009 |
| June 30, 2023 | 0.1733 |
| March 31, 2023 | 0.1513 |
| December 31, 2022 | 0.1421 |
| September 30, 2022 | 0.1293 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.2031 |
| March 31, 2022 | 0.1704 |
| December 31, 2021 | 0.1491 |
| September 30, 2021 | 0.1279 |
| June 30, 2021 | 0.0894 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | -1.566 |
| June 30, 2019 | -1.369 |
| March 31, 2019 | |
| December 31, 2018 | -1.670 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Marker Therapeutics, Inc. | 0.00 |
| Krystal Biotech, Inc. | 0.0065 |
| Immix Biopharma, Inc. | 0.0044 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 246.07M |
| Total Liabilities (Quarterly) | 60.01M |
| Shareholders Equity (Quarterly) | 186.06M |
| Current Ratio | 5.529 |
| Net Debt Paydown Yield | 0.07% |